Pacira Biosciences, Stock EBITDA
PCRX Stock | USD 17.55 0.17 0.98% |
Pacira BioSciences, fundamentals help investors to digest information that contributes to Pacira BioSciences,'s financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira BioSciences,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira BioSciences, stock.
Last Reported | Projected for Next Year | ||
EBITDA | 162.9 M | 171 M |
Pacira | EBITDA |
Pacira BioSciences, Company EBITDA Analysis
Pacira BioSciences,'s EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Pacira BioSciences, EBITDA | 162.9 M |
Most of Pacira BioSciences,'s fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pacira EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacira BioSciences, is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as EBITDA. Since Pacira BioSciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira BioSciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira BioSciences,'s interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
Pacira Ebitda
Ebitda |
|
According to the company disclosure, Pacira BioSciences, reported earnings before interest,tax, depreciation and amortization of 162.9 M. This is 81.43% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 95.82% higher than that of the company.
Pacira EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.Pacira BioSciences, is currently under evaluation in ebitda category among its peers.
Pacira BioSciences, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pacira BioSciences,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pacira BioSciences,'s managers, analysts, and investors.Environmental | Governance | Social |
Pacira BioSciences, Institutional Holders
Institutional Holdings refers to the ownership stake in Pacira BioSciences, that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pacira BioSciences,'s outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacira BioSciences,'s value.Shares | Marshall Wace Asset Management Ltd | 2024-06-30 | 971.1 K | Rock Springs Capital Management Lp | 2024-06-30 | 785 K | Nuveen Asset Management, Llc | 2024-06-30 | 711.2 K | Hhg Plc | 2024-06-30 | 698.4 K | Schroder Investment Management Group | 2024-06-30 | 616.8 K | Jpmorgan Chase & Co | 2024-06-30 | 600.6 K | Bank Of America Corp | 2024-06-30 | 559 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 554.4 K | Assenagon Asset Management Sa | 2024-09-30 | 553.1 K | Blackrock Inc | 2024-06-30 | 8 M | Vanguard Group Inc | 2024-09-30 | 5.3 M |
Pacira Fundamentals
Return On Equity | -0.11 | ||||
Return On Asset | 0.0417 | ||||
Profit Margin | (0.13) % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 1 B | ||||
Shares Outstanding | 46.17 M | ||||
Shares Owned By Insiders | 2.10 % | ||||
Shares Owned By Institutions | 97.90 % | ||||
Number Of Shares Shorted | 5.46 M | ||||
Price To Earning | 14.34 X | ||||
Price To Book | 1.08 X | ||||
Price To Sales | 1.17 X | ||||
Revenue | 674.98 M | ||||
Gross Profit | 393.23 M | ||||
EBITDA | 162.9 M | ||||
Net Income | 41.95 M | ||||
Cash And Equivalents | 316.39 M | ||||
Cash Per Share | 6.90 X | ||||
Total Debt | 586.04 M | ||||
Debt To Equity | 1.10 % | ||||
Current Ratio | 3.95 X | ||||
Book Value Per Share | 16.24 X | ||||
Cash Flow From Operations | 154.65 M | ||||
Short Ratio | 9.34 X | ||||
Earnings Per Share | (1.98) X | ||||
Price To Earnings To Growth | (3.83) X | ||||
Target Price | 18.0 | ||||
Number Of Employees | 711 | ||||
Beta | 0.82 | ||||
Market Capitalization | 810.34 M | ||||
Total Asset | 1.57 B | ||||
Retained Earnings | (106.8 M) | ||||
Working Capital | 412.61 M | ||||
Current Asset | 252.58 M | ||||
Current Liabilities | 149.79 M | ||||
Net Asset | 1.57 B |
About Pacira BioSciences, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.